On Mar. 15, 2021, Moderna announced that the first participants had been dosed in the Phase 1 study of mRNA-1283, the Companyﾒs next generation COVID-19 vaccine candidate.

This Phase 1 dose-ranging study assessed the safety and immunogenicity of mRNA-1283, a next-generation vaccine candidate against COVID-19. mRNA-1283 encodes for the portions of the SARS-CoV-2 spike protein critical for neutralization, specifically the Receptor Binding Domain (RBD) and N-terminal Domain (NTD).